中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

Association between intestinal barrier and bacterial translocation in patients with liver cirrhosis

DOI: 10.3969/j.issn.1001-5256.2019.08.046
Research funding:

 

  • Received Date: 2019-04-08
  • Published Date: 2019-08-20
  • Decompensated liver cirrhosis has various life-threatening complications such as spontaneous bacterial peritonitis, hepatic encephalopathy, and sepsis, and the development of such complications is closely associated with bacterial translocation. Pathological bacterial translocation in patients with liver cirrhosis is caused by the impairment of intestinal barrier function, and thus bacteria can cross the intestinal barrier and enter the mesenteric lymph nodes or other sites. Therefore, a better understanding of the association between intestinal barrier and bacterial translocation in liver cirrhosis can provide new theoretical support for the treatment of liver cirrhosis. This article discusses the four major components of the intestinal barrier, namely the mechanical barrier, the immune barrier, the chemical barrier, and the biological barrier, as well as their changes during bacterial translocation.

     

  • [1] LIU JQ, ZHOU SM. Research advances in intestinal flora in nonalcoholic fatty liver disease[J]. J Clin Hepatol, 2017, 33 (12) :2453-2456. (in Chinese) 刘嘉琪, 周少明.非酒精性脂肪性肝病肠道菌群的研究进展[J].临床肝胆病杂志, 2017, 33 (12) :2453-2456.
    [2] WIEST R, LAWSON M, GEUKING M. Pathological bacterial translocation in liver cirrhosis[J]. J Hepatol, 2014, 60 (1) :197-209.
    [3] OIKONOMOU T, PAPATHEODORIDIS GV, SAMARKOS M, et al. Clinical impact of microbiome in patients with decompensated cirrhosis[J]. World J Gastroenterol, 2018, 24 (34) :3813-3820.
    [4] ZHANG J, FENG Z, LIU P, et al. Research advances in the association between gut microbiota and complications after liver transplantation[J]. Ogran Transplantation, 2017, 8 (5) :399-401. (in Chinese) 张静, 冯哲, 刘鹏, 等.肠道菌群与肝移植相互作用研究进展[J].器官移植, 2017, 8 (5) :399-401.
    [5] LU BJ, ZHAO YH, AN YT, et al. Research advances in gut microbiota in liver cirrhosis and related complications[J]. J Clin Hepatol, 2018, 34 (11) :2433-2437. (in Chinese) 鲁冰洁, 赵亚红, 安泳潼, 等.肠道微生物在肝硬化及相关并发症中的研究进展[J].临床肝胆病杂志, 2018, 34 (11) :2433-2437.
    [6] SPADONI I, ZAGATO E, BERTOCCHI A, et al. A gut-vascular barrier controls the systemic dissemination of bacteria[J].Science, 2015, 350 (6262) :830-834.
    [7] FOUTS DE, TORRALBA M, NELSON KE, et al. Bacterial translocation and changes in the intestinal microbiome in mouse models of liver disease[J]. J Hepatol, 2012, 56 (6) :1283-1292.
    [8] ASSIMAKOPOULOS SF, TSAMANDAS AC, TSIAOUSSIS GI, et al. Altered intestinal tight junctions’expression in patients with liver cirrhosis:A pathogenetic mechanism of intestinal hyperpermeability[J]. Eur J Clin Invest, 2012, 42 (4) :439-446.
    [9] KARTHIKEYAN A, MOHAN P, CHINNAKALI P, et al. Elevated systemic zonula occludens 1 is positively correlated with inflammation in cirrhosis[J]. Clin Chim Acta, 2018, 480:193-198.
    [10] RAPARELLI V, BASILI S, CARNEVALE R, et al. Low-grade endotoxemia and platelet activation in cirrhosis[J]. Hepatology, 2017, 65 (2) :571-581.
    [11] RAM AK, POTTAKAT B, VAIRAPPAN B. Increased systemic zonula occludens 1 associated with inflammation and independent biomarker in patients with hepatocellular carcinoma[J]. BMC Cancer, 2018, 18 (1) :572.
    [12] ARAB JP, MARTIN-MATEOS RM, SHAH VH. Gut-liver axis, cirrhosis and portal hypertension:The chicken and the egg[J]. Hepatol Int, 2018, 12 (Suppl 1) :24-33.
    [13] TSIAOUSSIS GI, PAPAIOANNOU EC, KOUREA EP, et al. Expression ofα-defensins, CD20+B-lymphocytes, and intraepithelial CD3+T-lymphocytes in the intestinal mucosa of patients with liver cirrhosis:Emerging mediators of intestinal barrier function[J]. Dig Dis Sci, 2018, 63 (10) :2582-2592.
    [14] SHI H, LV L, CAO H, et al. Bacterial translocation aggravates CCl4-induced liver cirrhosis by regulating CD4+T cells in rats[J]. Sci Rep, 2017, 7:40516.
    [15] WANG S, CHARBONNIER LM, NOVAL RIVAS M, et al. My D88adaptor-dependent microbial sensing by regulatory T cells promotes mucosal tolerance and enforces commensalism[J]. Immunity, 2015, 43 (2) :289-303.
    [16] MUOZ L, BORRERO MJ, U'BEDA M, et al. Intestinal immune dysregulation driven by dysbiosis promotes barrier disruption and bacterial translocation in rats with cirrhosis[J]. Hepatology, 2018.[Epub ahead of print]
    [17] HARTMANN P, CHEN P, WANG HJ, et al. Deficiency of intestinal mucin-2 ameliorates experimental alcoholic liver disease in mice[J]. Hepatology, 2013, 58 (1) :108-119.
    [18] TELTSCHIK Z, WIEST R, BEISNER J, et al. Intestinal bacterial translocation in rats with cirrhosis is related to compromised Paneth cell antimicrobial host defense[J]. Hepatology, 2012, 55 (4) :1154-1163.
    [19] WANG J, HUANG N, XIONG J, et al. Caprylic acid and nonanoic acid upregulate endogenous host defense peptides to enhance intestinal epithelial immunological barrier function via histone deacetylase inhibition[J]. Int Immunopharmacol, 2018, 65:303-311.
    [20] U'BEDA M, LARIO M, MUOZ L, et al. Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats[J]. J Hepatol, 2016, 64 (5) :1049-1057.
    [21] SINGH J, METRANI R, SHIVANAGOUDRA SR, et al. Review on bile acids:Effects of the gut microbiome, interactions with dietary fiber, and alterations in the bioaccessibility of bioactive compounds[J]. J Agric Food Chem, 2019.[Epub ahead of print]
    [22] LU LG, HU JF. Research advances in the association between gut microbiota and bile acid[J]. J Intern Med Concepts Pract, 2018, 13 (6) :329-333. (in Chinese) 陆伦根, 胡江峰.肠道菌群与胆汁酸的研究进展[J].内科理论与实践, 2018, 13 (6) :329-333.
    [23] KAKIYAMA G, PANDAK WM, GILLEVET PM, et al. Modulation of the fecal bile acid profile by gut microbiota in cirrhosis[J]. J Hepatol, 2013, 58 (5) :949-955.
    [24] GIANNELLI V, DI GREGORIO V, IEBBA V, et al. Microbiota and the gut-liver axis:Bacterial translocation, inflammation and infection in cirrhosis[J]. World J Gastroenterol, 2014, 20 (45) :16795-16810.
    [25] RIDLON JM, ALVES JM, HYLEMON PB, et al. Cirrhosis, bile acids and gut microbiota:Unraveling a complex relationship[J]. Gut Microbes. 2013. 4 (5) :382-387.
    [26] BAJAJ JS, HEUMAN DM, HYLEMON PB, et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications[J]. J Hepatol, 2014, 60 (5) :940-947.
    [27] SARANGI AN, GOEL A, SINGH A, et al. Faecal bacterial microbiota in patients with cirrhosis and the effect of lactulose administration[J]. BMC Gastroenterol, 2017, 17 (1) :125.
    [28] MASLENNIKOV R, PAVLOV C, IVASHKIN V. Small intestinal bacterial overgrowth in cirrhosis:Systematic review and meta-analysis[J]. Hepatol Int, 2018, 12 (6) :567-576.
    [29] THEOCHARIDOU E, DHAR A, PATCH D. Gastrointestinal motility disorders and their clinical implications in cirrhosis[J].Gastroenterol Res Pract, 2017, 2017:8270310.
    [30] TETZ GV, RUGGLES KV, ZHOU H, et al. Bacteriophages as potential new mammalian pathogens[J]. Sci Rep, 2017, 7 (1) :7043.
    [31] YANG AM, INAMINE T, HOCHRATH K, et al. Intestinal fungi contribute to development of alcoholic liver disease[J]. J Clin Invest, 2017, 127 (7) :2829-2841.
  • Relative Articles

    [1]Yannan LI, Changzheng LI. Gut microbiota in hepatitis B cirrhosis[J]. Journal of Clinical Hepatology, 2025, 41(3): 552-555. doi: 10.12449/JCH250324
    [2]Jiongjiong BI, Yingjie MA. Characteristics of the composition of intestinal flora in cirrhotic patients with malnutrition[J]. Journal of Clinical Hepatology, 2024, 40(1): 83-88. doi: 10.12449/JCH240115
    [3]Quan ZHOU, Chunlin CAI, Jinqiang LI. Gut-liver axis: Intestinal microbial homeostasis and hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2023, 39(11): 2710-2717. doi: 10.3969/j.issn.1001-5256.2023.11.029
    [4]Guirong CHEN, Minggang WANG, Huaming LIN, Huiping YAN, Xiufeng WANG. Changes and pathogenic mechanism of intestinal flora in acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2023, 39(8): 1992-1998. doi: 10.3969/j.issn.1001-5256.2023.08.034
    [5]Ziwei GUO, Jiaxin ZHANG, Shuo LI, Xiaobin LI, Shun ZHU, Qian JIN, Xiaoke LI, Yongan YE. Research advances in intestinal flora and the development and prognosis of chronic hepatitis B[J]. Journal of Clinical Hepatology, 2022, 38(5): 1137-1142. doi: 10.3969/j.issn.1001-5256.2022.05.034
    [6]Guochao NIU, Donglei SUN, Xiaolan ZHANG. Influence of small intestinal bacterial overgrowth on liver cirrhosis and its treatment[J]. Journal of Clinical Hepatology, 2022, 38(9): 2146-2149. doi: 10.3969/j.issn.1001-5256.2022.09.038
    [7]Menghao LI, Kai LI, Shihao TANG, Zhengyu WANG, Wengang GUO, Zhanxin YIN, Guohong HAN. Changes in gut microbiota after transjugular intrahepatic portosystemic shunt in cirrhotic patients with mild hepatic encephalopathy in different prognosis groups[J]. Journal of Clinical Hepatology, 2021, 37(2): 326-330. doi: 10.3969/j.issn.1001-5256.2021.02.016
    [8]Yu LIU, Yuyi ZHANG, Ying ZOU, Wei YUAN, Hongying GUO, Xue MEI, Jiefei WANG, Zhiping QIAN. Association between intestinal microecology and spontaneous bacterial peritonitis[J]. Journal of Clinical Hepatology, 2021, 37(2): 425-428. doi: 10.3969/j.issn.1001-5256.2021.02.037
    [9]Li HongShan, Hu YiYang. Gut microecology: An important target of traditional Chinese medicine in the treatment of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(1): 14-18. doi: 10.3969/j.issn.1001-5256.2020.01.002
    [10]Luan YuTing, Cai WenJun, Jiang ShiLi, Zhao ZhangQing, Gu HongTu, Yuan JiLi, Xing Feng, Lu: Jing, Liu ChengHai, Liu Ping, Mu YongPing. A comparative study of intestinal flora between hepatitis B cirrhosis patients with or without ascites[J]. Journal of Clinical Hepatology, 2020, 36(7): 1520-1526. doi: 10.3969/j.issn.1001-5256.2020.07.015
    [11]Li Qiang, Zhu QingLiang, Zhang HaiLong, Deng MingMing, Hu Qing, Wang ZiJie. Characteristics of intestinal flora before and after transjugular intrahepatic portosystemic shunt in patients with liver cirrhosis[J]. Journal of Clinical Hepatology, 2020, 36(2): 333-337. doi: 10.3969/j.issn.1001-5256.2020.02.020
    [12]Guo XiaoXia, Hu Na, Lian XiaoXiao, Sun YuanPei, Li YuZhen, Lu: Lei, Ye YongAn, Li XiaoKe. Features of intestinal flora imbalance in patients with liver cirrhosis and related driving factors[J]. Journal of Clinical Hepatology, 2020, 36(7): 1527-1533. doi: 10.3969/j.issn.1001-5256.2020.07.016
    [13]Huang YunYi, Liu Yao, Zhang Qun, Shi Ke, Wang XianBo. Association of intestinal microecology with hepatic encephalopathy[J]. Journal of Clinical Hepatology, 2020, 36(4): 912-914. doi: 10.3969/j.issn.1001-5256.2020.04.045
    [14]Huang Qian, Zhang HaiBo, Li JingTao, Wei HaiLiang, Yan ShuGuang, Hui Yi, Chang ZhanJie. Research advances in the mechanism of action of intestinal microecology in intrahepatic cholestasis[J]. Journal of Clinical Hepatology, 2019, 35(10): 2355-2359. doi: 10.3969/j.issn.1001-5256.2019.10.050
    [15]Li YunPeng, Wang XinHong, Zhang DeKai. Influence of intestinal dysbacteriosis on liver cirrhosis[J]. Journal of Clinical Hepatology, 2019, 35(4): 887-890. doi: 10.3969/j.issn.1001-5256.2019.04.040
    [16]Zheng Wei, Zhang YongHong, Zhao Yan. Role of intestinal microflora in the pathogenesis of hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2019, 35(7): 1613-1615. doi: 10.3969/j.issn.1001-5256.2019.07.041
    [17]Luan YuTing, Cai WenJun, Xu Ying, Liu Ping, Mu YongPing. Role of intestinal flora in the development and progression of spontaneous bacterial peritonitis[J]. Journal of Clinical Hepatology, 2016, 32(8): 1622-1625. doi: 10.3969/j.issn.1001-5256.2016.08.045
    [18]Wang XiaoTong, Han Tao. A review of relationship between gut microecology and liver diseases[J]. Journal of Clinical Hepatology, 2015, 31(4): 642-645. doi: 10.3969/j.issn.1001-5256.2015.04.041
  • Cited by

    Periodical cited type(14)

    1. 费彦亢,俞可越,季明忠,张启航,房贺. 烧伤后肠道细菌移位及应用益生菌治疗细菌移位的研究进展. 上海医学. 2024(02): 117-122 .
    2. 王李晶子,李沛,张野,连建奇,张岚,吴沙沙,石聪敏,党肖. 慢加急性肝衰竭患者发生肺部感染的危险因素及预测模型的构建. 临床肝胆病杂志. 2024(06): 1196-1202 . 本站查看
    3. 罗鼎天,胡园敏,王伟国,阮水良,陆其明,杨志宏,方智芸,杨培秀. 益生菌对肝硬化腹水大鼠肠道机械屏障和肝脏合成功能的影响. 江苏医药. 2024(11): 1086-1088+1093+1076 .
    4. 黄耿雄,刘梦杰,马鸣,张雯博,金闻欣,朱咏琪,屈倩,吕伟杰,郭世宁. 裸花紫珠提取物对大肠杆菌感染肉鸡生长性能、免疫功能、抗炎能力及肠道屏障功能的影响. 动物营养学报. 2024(12): 7754-7769 .
    5. 何敏,张萍,何云. 枯草杆菌活菌胶囊联合恩替卡韦治疗乙型肝炎后肝硬化患者的效果. 慢性病学杂志. 2023(10): 1517-1520 .
    6. 王艳茹,安明伟,唐勇,汤卢伟. 基于肠道菌群探讨“六腑以通为用”的机理. 江西中医药大学学报. 2022(01): 11-14 .
    7. 仝鑫,陈绍斌. 肝硬化患者肠道微生态研究进展. 湖北医药学院学报. 2022(02): 210-214 .
    8. 王华强,谢芳,盛云峰,郑文凯,李平. 肝硬化患者发生血流感染的影响因素和病原学特点. 肝脏. 2021(03): 252-254+258 .
    9. 陈金强,李春达,李富强,陆利明,方斌,金智华. 肝硬化失代偿期患者并发自发性腹膜炎的危险因素分析及治疗. 中华全科医学. 2021(07): 1131-1134 .
    10. 毕宁,安小梅,王菁,陈会. 急性上消化道出血患者发生肺部感染的临床特点及危险因素分析. 中国现代医生. 2021(28): 59-62 .
    11. 史惠中,熊奇如,夏俊,张超,贾冉,俞广进,戴伟. 控制性低中心静脉压在原发性肝癌伴肝炎后肝硬化患者腹腔镜肝切除中的应用. 中国普通外科杂志. 2020(01): 27-34 .
    12. 戚励,裴冬梅,杨惠,沙楠楠,黄明星. 恩替卡韦联合美常安对乙型肝炎肝硬化患者肠道菌群及肠黏膜通透性的影响. 实用临床医药杂志. 2020(06): 61-65 .
    13. 赵丛林,张伯鹏,邹宁. 肝硬化患者合并医院内肺部感染的病原菌分布及危险因素. 临床与病理杂志. 2020(08): 2080-2084 .
    14. 戢晓,曾杨林,郭雅梵,孔凌祥,杨家印. 肝脏疾病与口腔菌群相互关系的研究进展. 中国普外基础与临床杂志. 2020(09): 1163-1168 .

    Other cited types(7)

  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (1144) PDF downloads(258) Cited by(21)
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return